CenteneSTU:QEN +0.39%73 EBITDA Margin % is 5.13% as of Mar. 2026, which is 40% above its 10-year median of 3.66. GuruFocus rates STU:QEN with a GF Score™ of 73/100 and a GF Value™ of €72.73 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 18 Healthcare Plans companies, Centene ranks worse than 88.89% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Centene's EBITDA for the
three
months ended in Mar. 2026 was €2,217 Mil. Centene's Revenue for the
three
months ended in Mar. 2026 was €43,202 Mil. Therefore, Centene's EBITDA margin for the quarter that ended in Mar. 2026 was 5.13%.
Centene (STU:QEN) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Centene EBITDA Margin % Related Terms
Centene EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Centene's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:QEN vs HUM, MOH, OSCR: EBITDA Margin % Comparison
For the Healthcare Plans subindustry, Centene's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Centene EBITDA Margin % vs Healthcare Plans Industry
For the Healthcare Plans industry and Healthcare sector, Centene's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Centene's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Centene (STU:QEN) has a EBITDA Margin % of 5.13% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Centene and its competitors. This is 40% above median its historical median of 3.66. According to the industry distribution chart, Centene ranks #16 out of 18 companies in the Healthcare Plans industry, placing it in the top 88.9%.
Is Centene's EBITDA Margin % too high?
Centene's current EBITDA Margin % of 5.13% is 40% above median its 10-year median of 3.66. The Healthcare Plans industry median EBITDA Margin % is 4.56. Centene's value of 5.13% is 12.6% above this industry median. Based on the distribution chart, Centene ranks #16 out of 18 companies in the Healthcare Plans industry, which is in the bottom quartile relative to peers. Overall, Centene has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Centene's EBITDA Margin % compare to HUM and MOH?
According to the Healthcare Plans industry distribution chart, Centene ranks #16 out of 18 companies for EBITDA Margin %. This places Centene in the lower half of its industry. The industry median EBITDA Margin % is 4.56. Centene's value of 5.13% is 12.6% above this benchmark. While the company's 10-year median is 3.66 vs. the industry median of 4.56, Centene has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Plans company?
The median EBITDA Margin % among Healthcare Plans companies is 4.56, based on 18 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Centene's current EBITDA Margin % of 5.13% is 12.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Centene and its competitors. For the Healthcare Plans industry, the median EBITDA Margin % is 4.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Centene's current EBITDA Margin % is 5.13%, which is 40% above median its own 10-year median of 3.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Centene stock overvalued right now?
Based on GuruFocus' analysis, Centene (STU:QEN) is currently considered Modestly Undervalued. The stock's GF Value™ is €72.73, compared to a current price of €57.20 — trading 21.4% below its estimated fair value. The current EBITDA Margin % is 5.13%, which is 40% above median its 10-year median of 3.66 and 12.6% above the Healthcare Plans industry median of 4.56. Centene's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Centene (STU:QEN), the current EBITDA Margin % is 5.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Centene (STU:QEN) Overvalued in 2026?
Based on GuruFocus' analysis, Centene stock appears to be undervalued.
The current stock price of €57.20 is trading 21.4% below its estimated GF Value™ of €72.73.
GuruFocus considers Centene to be Modestly Undervalued.
Key valuation signals for STU:QEN:
EBITDA Margin %: 5.13% (40% above median its 10-year median of 3.66)
GF Value™: €72.73 vs. price of €57.20 (21.4% below fair value)
Industry Position: 12.6% above the Healthcare Plans median (#16 of 18)
No single metric tells the full story. See the STU:QEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 20 million medical members as of December 2025, mostly in Medicaid (about 64% of membership), the individual exchanges (about 28%), and Medicare (about 5%). The company also provides Medicare Part D pharmaceutical plans.
73GF Score
Get the complete analysis for STU:QEN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:QEN has been successfully added to your 
